Riga, Kurbada str. 2B,
larifan.eu
Foundation year: 1997
NACE classifier: 21.10; 20.42
Authorization for wholesale distribution of medical products for human use, Authorization for active pharmaceutical ingredients manufacturing.
Turnover in the last 5 years
Thousands EUR
Source: Data collected by the Association of Latvian Chemical and Pharmaceutical Entrepreneurs from 2018 to 2022.
Number of employees in total and after education in the last 5 years
People
Source: Data collected by the Association of Latvian Chemical and Pharmaceutical Entrepreneurs from 2018 to 2022.
Ltd "Larifans" produces medical products and cosmetics, based on the original pharmaceutical active substance dsRNA Larifan. The original active substance is developed at the 1976, commercial production is being performed since 1994.
Larifan is an immunomodulator, interferon inducer of natural origin with a broad spectrum of action. Larifan is used in fields such as immunology, virology, oncology, etc. Larifan widely is used for the correction of the immune system at different viral disease mainly: herpes virus, influenza, encephalitis, hepatitis, papillomas (warts) and different sexually transmissible disease.
Main markets
- 1. Belarus
- 2. Georgia
- 3. Estonia
- 4. Lithuania
Target Markets
- 1. Malaysia
- 2. Uzbekistan
In which areas are looking for cooperation
Manufacturing of active pharmaceutical ingredients and pharmaceuticals
Investing in R&D
Thousands EUR
Source: Data collected by the Association of Latvian Chemical and Pharmaceutical Entrepreneurs from 2018 to 2022.
Products
Ointment - Larifan Ungo
Lip balm LARIFAN
Showing similar companies
By the industry in which it operates
Foundation year: 1997
NACE classifier: 21.10; 20.42
Turnover in the last 5 years
Thousands EUR
Source: Data collected by the Association of Latvian Chemical and Pharmaceutical Entrepreneurs from 2018 to 2022.
| 2018 | 2019 | 2020 | 2021 | 2022 |
|---|---|---|---|---|
| 174798 | 280308 | 420459 | 317869 | n/a |
Number of employees in total and after education in the last 5 years
People
Source: Data collected by the Association of Latvian Chemical and Pharmaceutical Entrepreneurs from 2018 to 2022.
| 2018 | 2019 | 2020 | 2021 | 2022 | |
|---|---|---|---|---|---|
| With higher education | 8 | 8 | 9 | 10 | n/a |
| With secondary and professional education | 7 | 7 | 8 | 4 | n/a |
| Number of employees in total | 15 | 15 | 17 | 17 | n/a |
In which areas are looking for cooperation
- Manufacturing of active pharmaceutical ingredients and pharmaceuticals
Export volume over the last 5 years
Data are not able
Data are not able
Main markets
- 1. Belarus
- 2. Georgia
- 3. Estonia
- 4. Lithuania
Target Markets
- 1. Malaysia
- 2. Uzbekistan
Investing in R&D
Thousands EUR
Source: Data collected by the Association of Latvian Chemical and Pharmaceutical Entrepreneurs from 2019 to 2023.
| 2018 | 2019 | 2020 | 2021 | 2022 |
|---|---|---|---|---|
| 17 | 9579 | 10 | n/a | n/a |
Larifāns SIA
Description about enterprise:
Ltd "Larifans" produces medical products and cosmetics, based on the original pharmaceutical active substance dsRNA Larifan. The original active substance is developed at the 1976, commercial production is being performed since 1994.
Larifan is an immunomodulator, interferon inducer of natural origin with a broad spectrum of action. Larifan is used in fields such as immunology, virology, oncology, etc. Larifan widely is used for the correction of the immune system at different viral disease mainly: herpes virus, influenza, encephalitis, hepatitis, papillomas (warts) and different sexually transmissible disease.
Valid certificates:
Authorization for wholesale distribution of medical products for human use, Authorization for active pharmaceutical ingredients manufacturing.
Products
Ointment - Larifan Ungo
Lip balm LARIFAN